Pharming announces positive interim analysis data from open-la... - 15 December 2022 17:00

LEIDEN, Netherlands, Dec. 15, 2022 /PRNewswire-AsiaNet/ -- V. Koneti Rao, MD, shared new evidence of long-term safety and hematologic response in patients who received leniolisib to treat APDS, a rare primary immunodeficiency Interim analysis demonstrated leniolisib to be well tolerated and indicated t...

  Hovione and GEA announce a strategic collaboration to advance ... - 15 December 2022 00:58

LISBON, Portugal, Dec. 14, 2022, /PRNewswire-AsiaNet/ -- Hovione and GEA today announced a strategic collaboration to advance Continuous Tableting. This partnership stemmed from a successful customer-supplier relationship spanning several years. It combines GEA´s engineering expertise with Hovione´s dev...

  Circulating Tumor Cell detection by Menarini Group's CELLSEARC... - 15 December 2022 00:00

Huntingdon Valley, PA, December 13, 2022, /PRNewswire-AsiaNet/-- Researchers at Dana-Farber Cancer Institute showed that enumeration of circulating tumor cells (CTCs) with Menarini Silicon Biosystems' CELLSEARCH(R) System and the CELLSERCH(R) Circulating Multiple Myeloma Cell (CMMC) Test* can be used to monitor...

  Japanese Healthcare Startup Ubie, Inc. Closes Extended Series ... - 08 December 2022 19:00

TOKYO, Dec. 8, 2022 /Kyodo JBN-AsiaNet/ -- Ubie, Inc., a Tokyo-based healthcare startup, announced on December 8 that it has closed its Series C round at $45 million by raising $19 million in an extension round. The new funding will enable Ubie to accelerate its growth and strengthen its p...

  Lost childhood: a 'tight-knit' network to combat abuse and dis... - 07 December 2022 23:29

ROME, Dec. 7, 2022 /PRNewswire-AsiaNet/ -- On Radar takes off, the first meeting of the Think Tank of Fondazione Internazionale Menarini Setting real changes in motion through dialogue among experts in order to tackle the unresolved issues of juvenile distress. This was the topic addre...

  Pharming announces publication of data from Phase 3 Study of l... - 07 December 2022 17:00

LEIDEN, Netherlands, Dec. 7, 2022 /PRNewswire-AsiaNet/-- Leniolisib was well tolerated and significant improvement over placebo was notable in the co-primary endpoints, reflecting a favorable impact on patients' immune dysregulation and deficiency The peer-reviewed publication heightens international...

  PGTG successfully develops SGF bone-derived factor to restore ... - 07 December 2022 16:23

BEIJING, Dec. 7, 2022 /PRNewswire-AsiaNet/ -- The bone-derived skeletal growth factor (SGF), jointly developed by a research facility under the direction of leading biochemist, academician and researcher Zhao Yufen and the Anhui-based research center of one of the world's health industry lead...

  Suvoda Launches eCOA-Specific Language and Design Toolkit as S... - 07 December 2022 11:00

PHILADELPHIA, Dec. 7, 2022 /PRNewswire- AsiaNet/ -- --Practical, innovative functionality seeks to alleviate eCOA burdens, reduce time-to-launch, and improve site, clinician, and patient experience. Suvoda LLC, a global clinical trial technology company that specializes in complex studies in the...

  Turn Biotechnologies Changes Paradigm in Skin Rejuvenation - 07 December 2022 01:00

MOUNTAIN VIEW, Calif., Dec. 6, 2022 /PRNewswire-AsiaNet/ -- -- Data unveiled at four industry conferences suggest a single ERA treatment may be more effective than combination therapies used today -- Biomarker analysis demonstrates ERA's regenerative impact on fibroblast prolifera...

  Sai Life Sciences releases its Sustainability Report 2022 - 05 December 2022 22:04

HYDERABAD, India, Dec. 5, 2022 /PRNewswire-AsiaNet/ -- Sai Life Sciences, a leading global Contract Research, Development & Manufacturing Organization [https://www.sailife.com/?utm_source=pr&utm_medium=web&utm_campaign=sustainability-report-2022](CRO/ CDMO), today announced the release of its Sust...